Severe asthma is a serious disease affecting about 5-10% of asthmatic patients. Often patients with this kind of asthma requires periodical courses or daily intake of oral corticosteroids, to control symptoms. In the last few years several biological drugs have been developed with the aim to decrease exacerbations and reduce or suspend intake of systemic steroids in severe asthmatic patients. Clinical trials demonstrated the efficacy and the safety of biological antibodies in asthma, but it is already known that randomized controlled trials alone are not sufficient to provide complete information on a drug
Asthma is a common chronic inflammatory condition of the airways affecting over 300 million people w...
Asthma is a heterogeneous disease with considerable variability noted in disease severity, patterns ...
The treatment landscape in severe asthma is changing rapidly, with multiple new therapies emerging t...
Biological drugs are approved to treat patients with severe uncontrolled asthma and are directed aga...
Asthma is one of the most common noncommunicable diseases; in the majority of patients it is well co...
Biologic Therapies for Severe Asthma Patients with severe asthma are at increased risk for a decreas...
Patients with severe asthma are at increased risk for a decreased quality of life, fixed airway obst...
By selectively targeting specific steps of the immune inflammation cascade, biologic drugs for sever...
Introduction: The precision medicine approach that is now mandatory for severe asthma management inc...
Asthma is a heterogeneous disease characterized by chronic airway inflammation that results in a wid...
: Around 5-10% of the total asthmatic population suffer from severe or uncontrolled asthma, which is...
Patients with severe asthma have a greater risk of asthma-related symptoms, morbidities, and exacerb...
Five to 10% of asthma patients remain symptomatic and/or have asthma attacks despite adequate inhale...
Severe asthma imposes a significant burden on patients, families and healthcare systems. Management ...
Patients with severe asthma experience severe symptoms and frequent exacerbations despite intensive ...
Asthma is a common chronic inflammatory condition of the airways affecting over 300 million people w...
Asthma is a heterogeneous disease with considerable variability noted in disease severity, patterns ...
The treatment landscape in severe asthma is changing rapidly, with multiple new therapies emerging t...
Biological drugs are approved to treat patients with severe uncontrolled asthma and are directed aga...
Asthma is one of the most common noncommunicable diseases; in the majority of patients it is well co...
Biologic Therapies for Severe Asthma Patients with severe asthma are at increased risk for a decreas...
Patients with severe asthma are at increased risk for a decreased quality of life, fixed airway obst...
By selectively targeting specific steps of the immune inflammation cascade, biologic drugs for sever...
Introduction: The precision medicine approach that is now mandatory for severe asthma management inc...
Asthma is a heterogeneous disease characterized by chronic airway inflammation that results in a wid...
: Around 5-10% of the total asthmatic population suffer from severe or uncontrolled asthma, which is...
Patients with severe asthma have a greater risk of asthma-related symptoms, morbidities, and exacerb...
Five to 10% of asthma patients remain symptomatic and/or have asthma attacks despite adequate inhale...
Severe asthma imposes a significant burden on patients, families and healthcare systems. Management ...
Patients with severe asthma experience severe symptoms and frequent exacerbations despite intensive ...
Asthma is a common chronic inflammatory condition of the airways affecting over 300 million people w...
Asthma is a heterogeneous disease with considerable variability noted in disease severity, patterns ...
The treatment landscape in severe asthma is changing rapidly, with multiple new therapies emerging t...